European Heart Journal Advance Access published online on January 28, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi116
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Biomedical and Surgical Sciences, Section of Cardiology, University of Verona, Piazzale Stefani 1, 37126 Verona, Italy; Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
* To whom correspondence should be addressed. Aims To compare, by meta-analytical techniques, the clinical impact of bare-metal stenting vs. balloon angioplasty for the treatment of lesions in small coronary arteries. Methods and results We included trials with random allocation and prospective comparison of angioplasty vs. stenting, reference vessel diameter <3 mm, and follow-up Conclusion Stenting is superior to balloon angioplasty for the treatment of small vessels, in particular after suboptimal angioplasty. However, MACE and RR rates remain high after stenting, and the advantage of stent over angioplasty is moderate. An optimal balloon angioplasty strategy (with provisional stenting) may achieve results not inferior to routine stenting.
Clinical research
Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials
2 S. Raffaele Hospital, ‘Vita e Salute’ University, University of Milan, Milan, Italy
3 Department of Biomedical and Surgical Sciences, Section of Cardiology, University of Verona, Piazzale Stefani 1, 37126 Verona, Italy
4 Department of Medicine, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA, USA
5 Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
Pierfrancesco Agostoni, E-mail: agostonipf{at}genie.it
![]()
Abstract
6 months. Random effect odds ratios (OR) for death, myocardial infarction (MI), repeat revascularization (RR), and major adverse cardiac events (MACEs) were computed. In a pre-specified subgroup analysis, we compared stenting with optimal (post-procedural stenosis <20%) and suboptimal (>20%) angioplasty. Thirteen studies (4383 patients) were selected. No differences were found in terms of death and MI, while MACEs, mainly driven by RR, were significantly less common after stenting (17.6%) than after angioplasty (22.7%), OR 0.71 (0.57-0.90). Heterogeneity among trials was present. When considering only optimal angioplasty, MACE rates were homogeneously similar, 17.9 vs. 21.1%, OR 0.86 (0.66-1.11). If angioplasty were suboptimal, MACEs were significantly more common after angioplasty (24%) than after stenting (17.3%), OR 0.62 (0.44-0.88).![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Togni, S. Eber, J. Widmer, M. Billinger, P. Wenaweser, S. Cook, R. Vogel, C. Seiler, F. R. Eberli, W. Maier, et al. Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1123 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-G. Chassot, A. Delabays, and D. R. Spahn Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction Br. J. Anaesth., September 1, 2007; 99(3): 316 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Elezi, A. Dibra, J. Mehilli, J. Pache, R. Wessely, A. Schomig, and A. Kastrati Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement: Results From a Large Cohort of Patients Treated With Sirolimus- or Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1304 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Shroff, D. J. Roebuck, I. Gordon, R. Davies, S. Stephens, S. Marks, M. Chan, M. Barkovics, C. A. McLaren, V. Shah, et al. Angioplasty for Renovascular Hypertension in Children: 20-Year Experience Pediatrics, July 1, 2006; 118(1): 268 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G L Biondi-Zoccai, M. Lotrionte, A. Abbate, L. Testa, E. Remigi, F. Burzotta, M. Valgimigli, E. Romagnoli, F. Crea, and P. Agostoni Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study BMJ, January 28, 2006; 332(7535): 202 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. De Luca, H. Suryapranata, G. Gregorio, H. Lange, and M. Chiariello Homocysteine and Its Effects on In-Stent Restenosis Circulation, November 8, 2005; 112(19): e307 - e311. [Full Text] [PDF] |
||||
![]() |
G. W. Stone, S. G. Ellis, L. Cannon, J. T. Mann, J. D. Greenberg, D. Spriggs, C. D. O'Shaughnessy, S. DeMaio, P. Hall, J. J. Popma, et al. Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial JAMA, September 14, 2005; 294(10): 1215 - 1223. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Moreno, C. Fernandez, and C. Macaya Coronary stenting in small vessels Eur. Heart J., August 1, 2005; 26(15): 1562 - 1562. [Full Text] [PDF] |
||||






